| Personalised Immunotherapy Platform (NCT06536257) | Melanoma Institute Australia | 2021-06-08 |
| BESPOKE Study of ctDNA Guided Immunotherapy (NCT04761783) | Natera, Inc. | 2021-05-28 |
| Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (NCT04655157) | Jason J. Luke, MD | 2021-05-28 |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (NCT04895709) | Bristol-Myers Squibb | 2021-05-27 |
| A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. (NCT04835805) | Genentech, Inc. | 2021-05-13 |
| RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma (NCT04762225) | Repertoire Immune Medicines | 2021-05-10 |
| A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma (NCT04834973) | QBiotics Group Limited | 2021-05-07 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. (NCT05061940) | Repertoire Immune Medicines | 2021-05-05 |
| Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy (NCT04605146) | Hospices Civils de Lyon | 2021-05-05 |
| Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) (NCT04700072) | Merck Sharp & Dohme LLC | 2021-05-03 |
| Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers (NCT07407166) | Institute of Oncology Ljubljana | 2021-05-01 |
| Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma (NCT05874817) | Novartis Pharmaceuticals | 2021-05-01 |
| PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine (NCT05697198) | Labcorp Corporation of America Holdings, Inc | 2021-04-19 |
| A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors (NCT04773951) | Shanghai Junshi Bioscience Co., Ltd. | 2021-04-12 |
| Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma (NCT04039672) | Hospices Civils de Lyon | 2021-04-02 |
| Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (NCT04495010) | Bristol-Myers Squibb | 2021-03-31 |
| Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (NCT03915678) | Institut Bergonié | 2021-03-31 |
| Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy (NCT04928365) | Blokhin's Russian Cancer Research Center | 2021-03-25 |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (NCT04772989) | Arcus Biosciences, Inc. | 2021-03-19 |
| A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors (NCT04731467) | Famewave Ltd. | 2021-03-19 |
| CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma (NCT04698187) | Regeneron Pharmaceuticals | 2021-03-11 |
| Surgery of Melanoma Metastases After Systemic Therapy (NCT04242329) | Vastra Gotaland Region | 2021-03-11 |
| Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients (NCT04385732) | Melanoma and Skin Cancer Trials Limited | 2021-03-03 |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors (NCT04725331) | Transgene | 2021-02-25 |
| Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma (NCT04658303) | Yana Najjar | 2021-02-24 |
| CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma (NCT04695977) | Regeneron Pharmaceuticals | 2021-02-24 |
| "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)" (NCT05299580) | Fondazione Melanoma Onlus | 2021-02-18 |
| DNX-2440 for Resectable Colorectal Liver Metastasis (NCT04714983) | DNAtrix, Inc. | 2021-02-15 |
| Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies (NCT05739006) | Biocad | 2021-02-08 |
| Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma (NCT04663126) | John O. Prior | 2021-02-01 |
| Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients (NCT04038619) | M.D. Anderson Cancer Center | 2021-02-01 |
| Immune Profiles Evolution Under Immunotherapy for Melanoma (NCT04576429) | Assistance Publique - Hôpitaux de Paris | 2021-01-27 |
| Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors (NCT04609566) | Seagen, a wholly owned subsidiary of Pfizer | 2021-01-26 |
| BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) (NCT04752826) | BioInvent International AB | 2021-01-25 |
| A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma (NCT04657991) | Pfizer | 2021-01-15 |
| Clinical Application of 18F-PEG3-FPN PET Imaging in Diagnosis and Staging of Malignant Melanoma (NCT04747561) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-01-12 |
| A Study of Adjuvant Melanoma Stakeholder Treatment Preferences (NCT05115006) | Bristol-Myers Squibb | 2021-01-07 |
| Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection (NCT04666272) | Novartis Pharmaceuticals | 2020-12-31 |
| Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients (NCT04526730) | H. Lee Moffitt Cancer Center and Research Institute | 2020-12-22 |
| Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity (NCT04631731) | Western Sydney Local Health District | 2020-12-15 |
| Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma (NCT04581382) | Mayo Clinic | 2020-12-14 |
| Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief (NCT04177056) | Hamilton Health Sciences Corporation | 2020-12-04 |
| Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NCT04722575) | Fondazione Melanoma Onlus | 2020-12-03 |
| Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients (NCT04604158) | Gillian Gresham | 2020-12-02 |
| OH2 Injection in Combination With HX008 for Melanoma. (NCT04616443) | Binhui Biopharmaceutical Co., Ltd. | 2020-12-01 |
| LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma (NCT04577807) | Istari Oncology, Inc. | 2020-11-17 |
| Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint Inhibitors (NCT04565769) | Aarhus University Hospital | 2020-11-12 |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy (NCT04596033) | Genocea Biosciences, Inc. | 2020-11-11 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| HL-085 in NRAS-mutated Advanced Melanoma (NCT05217303) | Shanghai Kechow Pharma, Inc. | 2020-11-02 |
| Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (NCT04417621) | Novartis Pharmaceuticals | 2020-10-30 |
| A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma (NCT04464759) | Ravi Amaravadi, MD | 2020-10-21 |
| MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer (NCT04729543) | Erasmus Medical Center | 2020-10-20 |
| Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) (NCT04364230) | Craig L Slingluff, Jr | 2020-09-28 |
| A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (NCT04370587) | ImmVira Pharma Co. Ltd | 2020-09-17 |
| AI-based Medical Device Validation for Early Melanoma Detection (NCT06221397) | AI Labs Group S.L | 2020-09-17 |
| Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma (NCT04546074) | Keio University | 2020-09-14 |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (NCT04114136) | Dan Zandberg | 2020-09-14 |
| Using QPOP to Predict Treatment for Sarcomas and Melanomas (NCT04986748) | National Cancer Centre, Singapore | 2020-09-08 |
| A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France (NCT04550247) | Bristol-Myers Squibb | 2020-09-02 |
| Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab (NCT04401995) | Diwakar Davar | 2020-09-02 |
| Quantitative Analysis of PET/CT Images of Immune Related Side Effects in Metastatic Melanoma Patients (NCT06207747) | Institute of Oncology Ljubljana | 2020-09-01 |
| BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs (NCT04473027) | University Hospital, Ghent | 2020-09-01 |
| Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target? (NCT04477876) | Assistance Publique - Hôpitaux de Paris | 2020-09-01 |
| A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma (NCT04756934) | Taizhou HoudeAoke Biomedical Co., Ltd. | 2020-08-20 |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (NCT04504669) | AstraZeneca | 2020-08-18 |
| Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma (NCT04594187) | M.D. Anderson Cancer Center | 2020-08-07 |
| Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma (NCT03878719) | Pfizer | 2020-08-03 |
| Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (NCT04410445) | Nektar Therapeutics | 2020-07-27 |
| Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies (NCT04370704) | Incyte Corporation | 2020-07-27 |
| A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (NCT04544748) | AO GENERIUM | 2020-07-22 |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S (NCT04430842) | Quadriga Biosciences, Inc. | 2020-07-20 |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (NCT04483778) | Seattle Children's Hospital | 2020-07-13 |
| Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma (NCT04407247) | M.D. Anderson Cancer Center | 2020-07-09 |
| Microbiome Immunotherapy Toxicity and Response Evaluation (NCT04107168) | CCTU- Cancer Theme | 2020-07-08 |
| Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access (NCT04420273) | Northwestern University | 2020-07-02 |
| Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) (NCT04305054) | Merck Sharp & Dohme LLC | 2020-07-01 |
| Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (NCT04303169) | Merck Sharp & Dohme LLC | 2020-06-26 |
| Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) (NCT04305041) | Merck Sharp & Dohme LLC | 2020-06-26 |
| Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment (NCT04435964) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2020-06-25 |
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab (NCT04074967) | Dan Zandberg | 2020-06-11 |
| Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic (NCT04474301) | M.D. Anderson Cancer Center | 2020-06-11 |
| Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors (NCT04860076) | Asylia Diagnostics BV | 2020-06-06 |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (NCT04720768) | Peter MacCallum Cancer Centre, Australia | 2020-06-04 |
| PVSRIPO in Combination With Nivolumab in Melanoma (NCT04125719) | Darell Bigner | 2020-06-01 |
| Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma (NCT04478318) | University of California, Davis | 2020-06-01 |
| Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases (NCT03754140) | Melanoma Institute Australia | 2020-05-20 |
| Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors (NCT04348916) | Oncorus, Inc. | 2020-05-20 |
| Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma (NCT04397770) | Peking University Cancer Hospital & Institute | 2020-05-01 |
| Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma. (NCT03758729) | Samsung Medical Center | 2020-05-01 |
| The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma (NCT04357509) | Peking University Cancer Hospital & Institute | 2020-05-01 |
| Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients (NCT04291105) | Vyriad, Inc. | 2020-04-24 |
| Family Lifestyles, Actions, and Risk Education Intervention: Version 2 (NCT04201223) | University of Utah | 2020-04-07 |
| Atypical MOLes and Melanoma Early Detection Study (MoleMed) (NCT04353050) | Russian Academy of Medical Sciences | 2020-04-01 |
| PD-L1 Expression in Cancer (PECan Study). (NCT04436406) | Guy's and St Thomas' NHS Foundation Trust | 2020-03-11 |
| Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma (NCT04091750) | Georgetown University | 2020-03-02 |
| Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer (NCT04261179) | Anna Cruceta | 2020-03-01 |
| A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NCT04250246) | Italian Network for Tumor Biotherapy Foundation | 2020-03-01 |
| DERM Health Economics Study (NCT04123678) | Skin Analytics Limited | 2020-02-26 |